Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia

Leukemia Research
Maryam NourizadehJamshid Hadjati

Abstract

Leukemic cells from AML patients can be differentiated to dendritic cells (DCs). Such DCs have potential for immunotherapy of patients. Blasts from 15 AML patients were differentiated into DCs and matured by different TLR agonists. We could generate AML-DCs from 73% of patients mostly with M4 or M5 subtypes. The DC recoveries ranged from 28% to 50%. The results showed that concomitant use of TLR4 and TLR7/8 agonists induced proficient DCs. Therefore, a combination of TLR4 and 7/8 agonists can be considered as an appropriate maturation cocktail for AML-DC production in order to use in the immunotherapy of AML patients.

References

Nov 5, 1999·The New England Journal of Medicine
Sep 7, 2002·Journal of Immunological Methods·Thomas G BergerBeatrice Schuler-Thurner
Jun 9, 2004·Critical Reviews in Oncology/hematology·Matthew SmithWolfgang Kern
Apr 2, 2005·Nature Reviews. Immunology·Jacques Banchereau, A Karolina Palucka
Nov 29, 2005·Trends in Immunology·David van DuinAlbert C Shaw
Feb 10, 2006·Cancer Immunology, Immunotherapy : CII·Saskia J A M SantegoetsTanja D de Gruijl
Jul 18, 2006·Heart·F BreuckmannR Erbel
Dec 28, 2006·Journal of Biochemistry·Taro Kawai, Shizuo Akira
Mar 7, 2007·Expert Review of Anticancer Therapy·Anita SchmittMichael Schmitt
Mar 21, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Theresia M WestersArjan A van de Loosdrecht
Apr 14, 2007·Journal of Translational Medicine·Anke ZobywalskiDolores J Schendel
May 13, 2008·Leukemia Research·Willemijn van den AnckerArjan A van de Loosdrecht
Sep 23, 2008·Pathology Oncology Research : POR·Kambiz BagheriSeyyed Mohammad Moazzeni
Apr 27, 2011·Cancer Immunology, Immunotherapy : CII·Evelien L J SmitsBarbara-Ann Guinn

❮ Previous
Next ❯

Citations

Nov 28, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ali MemarianMahmood Jeddi-Tehrani
Dec 25, 2012·Journal of Cancer Research and Clinical Oncology·Ulf SchnetzkeSebastian Scholl
Jun 30, 2016·International Journal of Molecular Sciences·Lisa PleyerRichard Greil
Sep 28, 2017·Stem Cells International·Nicola Stefano FracchiollaAgostino Cortelezzi
Jul 7, 2020·Frontiers in Immunology·Luana Chiquetto Paracatu, Laura G Schuettpelz
Jan 15, 2021·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Daniel Christoph Amberger, Helga Maria Schmetzer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.